NCT05112965

An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

An Open-Label, Multicenter Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

• Status: Active Not Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 49 (actual)
• Sponsor: Hoffmann-La Roche · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, multicenter, non-randomized extension study. Participants receiving atezolizumab monotherapy or atezolizumab combined with other agent(s) or comparator agent(s) in a Genentech or Roche-sponsored study (the parent study), who are eligible to continue treatment and do not have access to the study treatment locally, continue to receive study treatment in this extension study.

Conditions

• Neoplasms

Interventions

Type	Name	Description
DRUG	Atezolizumab	Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study at the time of participant discontinuation from the parent study closure.
DRUG	Bevacizumab	Bevacizumab will be administered as directed per the parent study.
DRUG	Pemetrexed	Pemetrexed will be administered as directed per the parent study.
DRUG	Paclitaxel	Paclitaxel will be administered as directed per the parent study.
DRUG	Enzalutamide	Enzalutamide will be administered as directed per the parent study.

Timeline

• Start date: 2021-12-01
• Primary completion: 2027-06-30
• Completion: 2027-06-30
• First posted: 2021-11-09
• Last updated: 2026-04-06

Locations

17 sites across 1 country: China